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Introduction
Over 90% of Alzheimer’s disease (AD) cases are sporadic rather 
than attributable to a single gene mutation. In these cases, as for 
many other sporadic adult-onset neurodegenerative diseases, 
the pathological changes are likely to be caused by a combina-
tion of environmental and genetic factors that activate variably 
independent pathogenic pathways that increase neuronal 
vulnerability to damage and death1. One major genetic risk 
factor for sporadic disease is the ε4 allele of APOE2. Aside from 
APOE, genome-wide association studies (GWAS), have linked 
single nucleotide polymorphisms (SNPs) in over 20 genetic loci 
to AD susceptibility3.
A common theme across neurodegenerative diseases is altera-
tions in neuronal connectivity that can give rise to clinical 
symptoms before neuronal loss4,5. Targeting the processes 
responsible for the changes in neuronal connectivity is a key 
therapeutic aim, before consequential axonal loss and neuro-
nal death cause irreversible disability in patients with neuro-
degenerative disease6,7. A crucial step in this transition from 
potentially reversible to irreversible disease is the disruption 
in axonal delivery of membrane-bound organelles from the 
neuronal soma to the synapse. The development of such dis-
ruption has been recognised pathologically in brain tissue, 
including in AD8, by the formation of axonal swellings at an 
early stage in the disease process.
Kinesin superfamily motor proteins (KIFs) are responsible for 
most anterograde protein transport within the axon of various 
cellular cargoes, including synaptic and structural proteins9. 
There are at least 38 different neuronally-enriched KIFs which 
contain a conserved microtubule-binding domain and a motor 
domain at their amino (NH2-) terminus, which hydrolyses ATP 
in order to generate motile forces to shift associated cargoes 
along the axon, via microtubule tracks10. The heterogeneous 
tail (COOH-terminal) domain of KIFs determines their cargo- 
binding specificity11.
Early disturbances in axonal transport are a feature of several 
neurodegenerative diseases12–14, and studies have linked KIF 
dysregulation to AD15,16. Conventional kinesin member KIF5A 
transports several cargoes, including APP and β- and γ- secre-
tases, by complexing with kinesin light chain-1 (KLC1)17,18. 
Deletion of the KLC1 subunit in mice leads to early selective 
axonal transport defects, resulting in a disorganised neuronal 
cytoskeleton with APP, neurofilament (NF) and hyperphos-
phorylated tau accumulation19. Mice transgenic for human 
APP with mutations that cause familial AD develop abnormal 
axonal swellings positive for KLC1 and structural axonal com-
ponent phosphorylated NF-H, long before AD pathology can be 
detected8,20.
Single nucleotide polymorphisms (SNPs) in the region of 
the KLC1 gene have been linked to AD susceptibility; in 
particular, rs8702 has been shown to predict conversion of mild 
cognitive impairment (MCI) to AD16,21,22. Our previous studies 
have shown that SNPs within the KIF5A gene locus, linked to 
multiple sclerosis (MS) susceptibility, influence KIF5A expression 
in post-mortem brain23,24.
We and others have found KIF5A expression to be increased 
in post-mortem AD and PD tissue25,26. KIF members show a 
degree of functional redundancy, such that more than one KIF 
may transport a specific cargo27. We therefore suggested that 
KIF5A might be upregulated in AD as compensatory protec-
tive response to defects in other, interoperable, axonal transport 
proteins, facilitating the transport and clearance of aggregating 
cargoes in the cell body and axon. In support of this hypothesis, 
we showed that KIF5A levels in both MS and AD correlated 
inversely with the amount of cargo APP24,25. KIF5A shares 
many cargoes with anterograde motor protein KIF1B, such as 
mitochondria and synaptic vesicle proteins, and it can transport 
cargoes without complexing to KLC19,28. 
In this study we aimed to determine whether KLC1 levels are 
altered in AD, the relationship between the levels of KLC1 
and KIF5A, and whether expression of KLC1 in the cerebral 
cortex is influenced by KLC1 polymorphisms, which have been 
linked to AD susceptibility.
Methods
Study cohort
Samples of midfrontal cortex (Brodmann area 8; 500mg) were 
obtained from the South West Dementia Brain Bank (Bristol, 
UK), under the terms of South West - Central Bristol Research 
Ethics Committee approval no 08/H0106/28+5. Our previous 
studies indicated an influence of post-mortem delay (PMD) on 
mRNA and protein expression in brain tissue25. Therefore, cases 
with a PMD >72 h were excluded from analysis. We studied 
47 cases of AD (in which, AD neuropathological change was 
an adequate explanation of dementia, according to National 
Institute on Aging-Alzheimer’s Association guidelines29), and 39 
age-matched controls with no history of cognitive impairment 
(Table 1).
RNA and protein extraction
Both RNA and protein were extracted from each sample by 
use of the Paris™ Kit (ThermoFisher Scientific; AM1921), 
according to the manufacturer’s instructions. Samples were 
weighed, divided into 2x 50 mg portions and placed in 2 ml 
homogenisation tubes, pre-filled with 5x 2.3 mm silica beads 
(Stratech Scientific; 11079125z-BSP) and 300 µL of Paris™ 
kit lysis buffer, with the addition of Halt™ Protease and 
phosphatase inhibitor cocktail and 0.5M EDTA (1:100) 
(ThermoFisher Scientific; 78440). Samples were homog-
enised using a Precellys®24 automated homogeniser (Stretton 
Scientific). Samples were subsequently centrifuged (Sorvall 
ST 16R) at 10,000 xg for 2 min at 4°C and the soluble protein 
supernatant removed and stored at -80°C until required. The 
remaining homogenate was taken through the additional 
manufacturer’s steps for extraction and elution of RNA, before 
storage at -80°C.
gDNA extraction
An approximately, 2 mm slice was taken from each brain sample 
and gDNA extracted using the TaqMan® Sample-to-SNP™ 
Kit (ThermoFisher Scientific; 4403313). Cortex was placed in 
lysis buffer, briefly centrifuged and incubated for 3 min at 95°C, 
before addition of DNA stabilising solution. Samples were then 
stored at -20°C until use. 
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Table 1. Clinical characteristics of Alzheimer’s 











C 1 62 M 4 0
C 2 95 F 46 0
C 3 78 F 24 2
C 4 64 M 12 2
C 5 64 M 16 0
C 6 90 M 45 2
C 7 64 M 23 2
C 8 77 M 55 1
C 9 78 M 12 2
C 10 73 M 36 2
C 11 88 F 62 2
C 12 88 F 72 0
C 13 93 F 18 2
C 14 88 F 28 2
C 15 82 M 30 2
C 16 84 M 48 3
C 17 90 M 48 2
C 18 75 M 48 2
C 19 89 F 15 2
C 20 73 M 33 1
C 21 69 M 66 2
C 22 73 F 59 1
C 23 83 F 24 2
C 24 82 M 3 2
C 25 79 M 24 -
C 26 43 F 12 -
C 27 84 F 17 1
C 28 82 F 37 2
C 29 78 M 48 1
C 30 82 M 56 2
C 31 76 M 23 2
C 32 91 F 60 2
C 33 77 M 10 3
C 34 75 M 6 3
C 35 78 M 21 -
C 36 93 F 53 3
C 37 90 M 5.5 2
C 38 90 F 67.25 1
C 39 83 M 47.75 2
Mean 80 (+/- 11) - 34 (+/- 20) - 
AD 1 89 F 71 5
AD 2 78 F 9 5
AD 3 81 F 42 6











AD 5 77 F 43 4
AD 6 96 F 53 4
AD 7 87 F 67 5
AD 8 79 F 70 3
AD 9 81 M 29 4
AD 10 91 F 70 5
AD 11 78 F 35 6
AD 12 83 F 43 5
AD 13 70 F 25 6
AD 14 78 F 4 5
AD 15 69 M 48 5
AD 16 74 M 50 5
AD 17 80 F 21 5
AD 18 95 M 48 3
AD 19 89 F 4 6
AD 20 79 M 28 6
AD 21 85 M 66 6
AD 22 81 F 66 4
AD 23 80 M 31 6
AD 24 90 F 21 4
AD 25 57 F 24 5
AD 26 54 F 24 6
AD 27 84 F 20 5
AD 28 93 M 20 3
AD 29 80 M 5 6
AD 30 87 F 55 6
AD 31 74 M 24 5
AD 32 78 F 21 5
AD 33 89 F 39 5
AD 34 84 M 64 5
AD 35 73 F 38 5
AD 36 68 M 61 6
AD 37 83 M 48 5
AD 38 74 M 48 5
AD 39 78 M 49 6
AD 40 78 M 50 6
AD 41 85 M 50 6
AD 42 98 F 21 5
AD 43 83 F 32 6
AD 44 69 M 12 5
AD 45 87 F 28 6
AD 46 84 F 21 6
AD 47 84 F 22 5
Mean 81 (+/- 9) - 37 (+/- 19) - 
Abbreviations: AD: Alzheimer’s disease; C: control; F: female; 
hrs: hours; M: male; yrs: years.
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Complementary DNA (cDNA) generation
Extracted RNA was quantified using the Qubit® RNA HS 
Assay Kit (ThermoFisher Scientific; Q32852) and Qubit® 4.0 
fluorometer (excitation 600-645 nm and emission 665-720 nm) 
(ThermoFisher Scientific; Q33226), according to the manu-
facturer’s instructions. Quantified RNA samples were subse-
quently treated with recombinant RNase-free DNase I (10,000U; 
Sigma Aldrich; 4716728001) and 50 mM MgCl2 solution 
(Bioline; BIO-37026) to remove any trace DNA. Treated RNA 
was diluted to achieve 100 ng/50 µL for reverse transcription into 
cDNA using the High Capacity cDNA Reverse Transcription Kit 
(ThermoFisher Scientific; 4368814), according to the manufac-
turer’s instructions. 50 µL of reverse transcription mastermix 
was added to diluted RNA samples before thermal cycling on 
a StepOnePlus PCR system™ for cDNA generation. The cycling 
conditions were holding at 25°C for 10 min, 37°C for 120 min, 
followed by 85°C for 5 min. cDNA was stored at -80°C until use.
Quantitative real-time PCR (qPCR)
cDNA (2 ng/µL) was diluted to a final volume of 20 µL in 
TaqMan® 2x Fast Advanced Master Mix (ThermoFisher Scien-
tific; 4444557) and TaqMan® gene expression probe solution 
(FAM-MGB dye-labelled, ThermoFisher Scientific) for 
KIF5A (Hs01007893_m1), KLC1 (Hs00194316_m1) RBFOX3 
(Hs01370653_m1) and GAPDH (Hs02758991_g1). qPCR was 
performed on a StepOnePlus™ Real-Time PCR system with 
StepOne software v2.1 (ThermoFisher Scientific), on a FAST 
ramp speed, (Holding at 50°C for 2 min, 95°C for 2 min, cycling 
(x40) at 95°C for 1 s, followed by 60°C for 20 s). As the genes of 
interest are expressed predominantly neuronally, gene expres-
sion was calculated relative to that of a neuron-specific calibra-
tor gene, encoding neuronal nuclear protein NeuN (RBFOX3), by 
the 2-ΔΔct method. In addition, RBFOX3 levels were normalised 
to ubiquitous house-keeping gene GAPDH to assess any influence 
of PMD on gene expression.
Genotyping
Extracted gDNA was genotyped using qPCRBIO Genotyping 
Mix Hi-ROX (PCR Biosystems; PB20.42-05) and inventoried 
TaqMan® SNP Genotyping Assays (ThermoFisher Scientific; 
4351379) for rs8702 (C__11467163_10), rs8007903 (C___
2169408_10), rs12368653 (C__26237749_10) and rs4646536 
(C__25623453_10) (proxy for rs703842), according to the 
manufacturer’s instructions. Genotyping was performed on a 
StepOnePlus™ Real-Time PCR system with StepOne software 
v2.1 (ThermoFisher Scientific), on a FAST ramp speed (Hold-
ing at 60°C for 30 s, 95°C for 3 min, cycling (x40) at 95°C for 
15 s, 60°C for 1 min, holding at 60°C for 30 s).
Western blot
Validation of primary antibody specificity for use in dot blot 
analysis was verified using western blot, as per previous studies25. 
Protein homogenates were diluted 1:1 with Laemmli 2x 
sample buffer (Sigma-Aldrich Ltd; S3401) and heated to 95°C 
to denature the protein. Samples and BLUeye Prestained Protein 
Ladder (Geneflow; S6-0024) were loaded onto mini-Protean 
TGX gels (4–20%) (Biorad; 456-1093) in a Mini-PROTEAN 
Tetra cell (Biorad; 1658004), filled with Tris/Glycine/SDS 
running buffer (Biorad; 161-0732). The gel was run at 150 V 
until the dye front reached the bottom of the gel, before protein 
transfer onto nitrocellulose membrane for 90 min at 350 mA. 
Membranes were blocked in 5% BSA/Tris-buffered saline- 
Tween 20 (TBS-T) or 5% milk/TBS-T, for 1 h at room 
temperature. Primary antibodies were reconstituted in membrane 
blocking solution (detailed in Table 2) and added overnight at 
4°C. The primary antibodies used were: mouse anti-AβPP 
(ThermoFisher Scientific; 13-0200), mouse anti-GAPDH 
(Abcam; Ab9484); mouse anti-PHF-TAU (ThermoFisher 
Scientifc UK; MN1020), rabbit anti-KIF5A (Sigma-Aldrich Ltd; 
HPA004469), rabbit anti-KLC1 (Abcam; Ab174273) and rabbit 
anti-NeuN (Abcam; Ab177487). Bound primary antibody 
was detected by incubation with HRP-conjugated secondary 
antibodies for 1 h at room temperature (as detailed in 
Table 2). Protein expression was visualised using a chemi-
luminescence Clarity™ Western ECL Substrate (Biorad; 
1705060). Antibodies displayed bands relative to their reported 
molecular weight, as described on manufacturer data sheets 
(Figure 1).
Table 2. Antibodies used for immunoblotting.
Antigen Species Blocking antibody 
WB/DB 
concentration Company RRID 
HRP-conjugated 
secondary RRID 
APP Mouse monoclonal 5% milk/TBS-T 1:500
ThermoFisher 
Scientific; 13-0200 AB_2532993 Goat anti-mouse 
IgG 1:5000 Abcam; 
Ab6789
AB_955439
GAPDH Mouse monoclonal 5% milk/TBS-T 1:5000 Merck; MAB374 AB_2107445
PHF-Tau Mouse monoclonal 5% BSA/TBS-T 1:500
ThermoFisher 
Scientific; MN1020 AB_223647
Goat anti-mouse IgG 
1:10,000 Stratech;  
115-035-146-JIR
AB_2307392
KIF5A Rabbit polyclonal 5% milk/TBS-T 1:1000
Sigma-Aldrich; 
HPA004469; AB_1079212
Goat anti-rabbit IgG 
1:10,000 Abcam; 
ab7090
AB_955417KLC1 Rabbit monoclonal 5% BSA/TBS-T 1:5000 Abcam; Ab174273 AB_2783556
NeuN Rabbit monoclonal 5% milk/TBS-T 1:5000 Abcam; Ab177487 AB_2532109
Abbreviations: APP: amyloid precursor protein; BSA: bovine serum albumin; DB: dot blot; KIF: kinesin superfamily protein; KLC1: kinesin light chain-1; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; NeuN: neuronal nuclear protein; PHF: paired-helical filament; RRID: Research Resource Identifiers; T: TBS-T:  
tris-buffered saline-tween; WB: western blot.
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Dot blot
Dot blot was performed using a Bio-Dot Microfiltration mani-
fold (Biorad), according to the manufacturer’s instructions. 
Nitrocellulose membrane was pre-soaked in 1x TBS and placed 
in the manifold, before addition of 100 µL of protein homoge-
nate/well (diluted 1:200 with 1x TBS). After microfiltration for 
90 min, the membrane was removed and placed in blocking 
antibody, before antibody incubation (Table 2), as per the western 
blot protocol. Protein expression was visualised on a Biorad 
Universal III Bioplex imager, using a chemiluminescence 
Clarity™ Western ECL Substrate (Biorad). Image Lab™ 5.0 
software (Biorad) was used for densitometric protein analysis. 
Integrated density values were expressed relative to the neuro-
nal nuclear protein NeuN. In addition, NeuN protein levels were 
normalised to ubiquitous protein GAPDH to study any effect of 
PMD on protein expression.
Enzyme-linked immunosorbent assay (ELISA)
AD frontal tissue (200 mg) was homogenised in TBS extraction 
buffer to obtain the soluble protein fraction and the protein pel-
let was homogenised in guanidine to obtain the insoluble 
fraction, as previously described25,30. Sandwich ELISA was used 
to measure total Aβ in the fractions, with mouse monoclonal 
anti-Aβ (4G8 clone) (Biolegend; 800712; RRID: AB_2734548), 
for the capture step and biotinylated anti-human Aβ monoclonal 
antibody (10H3 clone) (ThermoFisher Scientific; MN1150B; 
RRID: AB_223641), for the detection step, as previously 
described31.
Immunoperoxidase staining of paraffin sections
7 µm sections from frontal cortex were dewaxed, hydrated, and 
immersed in 3% hydrogen peroxide in methanol for 30 min to 
block endogenous peroxidase activity. Sections were subse-
quently rinsed in running tap water and pre-treated with sodium 
citrate buffer in the microwave (0.01 M, pH 6.0, 5 min) to 
unmask antigenic sites, then rinsed in PBS. Immunostaining 
was performed using VECTASTAIN® Universal Elite® ABC 
Kit (Vector Laboratories; PK-6200). Non-specific binding was 
blocked using horse serum for 30 min at room temperature, 
before incubation overnight at 4°C with anti-mouse mono-
clonal PHF-tau (1:2000) (ThermoFisher Scientific; MN1020; 
RRID: AB_223647), diluted in PBS. Sections were rinsed in 
PBS and incubated for 20 min with VECTASTAIN® bioti-
nylated universal secondary antibody, followed by 20 min with 
VECTASTAIN® Elite® ABC complex (both Vector Laboratories; 
PK-6200), before a final 7 min with 3,3’-diaminobenzidine 
(DAB) (Vector Laboratories; SK4100). Sections were washed 
in water, immersed in copper sulphate DAB enhancer for 4 min 
(0.16 M Copper (II) sulphate 5-hydrate/0.12 M sodium chloride) 
and counterstained with Gills haematoxylin II (Sigma-Aldrich 
Ltd; GHS216) for 15 s. Sections were subsequently dehydrated, 
cleared and mounted in Clearium® (Leica Biosystems; 3801100). 
Controls in each run included sections incubated overnight in 
PBS instead of the primary antibody.
Immunohistochemical analysis
The percentage field fraction immunopositive for PHF-tau 
(insoluble tau load) was assessed in the cortex of frontal sec-
tions from AD and controls by computer-assisted image analysis 
using Histometrix software (Kinetic Imaging, Nottingham, 
UK) driving a Leica DM microscope with a motorised stage, 
as previously described32,33. The area to be analysed was selected 
at low-magnification (x2.5) and the threshold for PHF-tau 
labelling density calibrated at high magnification (x20). The 
Figure 1. Antibody specificity. western blots performed using AD protein homogenates, derived from mid-frontal cortex. Predicted molecular 
weight of APP 110-135kDa. Antibody used for detection was mouse anti-APP (1:2000), ThermoFisher Scientific; 13-0200 (A). Predicted 
molecular weight of GAPDH 37kDa. Antibody used for detection was mouse anti-GAPDH (1:5000), Merck; MAB374 (B). Predicted molecular 
weight of KIF5A 107kDa and 117kDa. Antibody used for band detection was rabbit anti-KIF5A (1:1000), Sigma-Aldrich; HPA004469 (C). 
Predicted molecular weight of KLC1 60-70kDa. Antibody used for detection was rabbit anti-KLC1 (1:5000), Abcam; Ab174273 (D). Predicted 
molecular weight of NeuN 48kDa. Antibody used for detection was rabbit anti-NeuN (1:5000), Abcam; Ab177487 (E). Predicted molecular 
weight of paired-helical filament tau 45-65kDa. Antibody used for detection were mouse anti-PHF-Tau (1:500), ThermoFisher Scientific; 
MN1020 (F). APP: amyloid precursor protein; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; kDa: kilodaltons; KIF: kinesin superfamily 
motor protein; KLC1: kinesin light chain-1; MW: molecular weight; PHF: paired helical filament; NeuN: neuronal nuclear protein.
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software was programmed to measure tau load in 30 random 
regions (x20 objective fields) within the selected area and 
determine the cumulative area fraction with a density exceeding 
the threshold value.
Statistical analysis
Univariate mRNA and protein analysis were performed using 
GraphPad Prism 5™ (GraphPad Software Inc.; San Diego, 
USA). Data normality was tested using the Shapiro-Wilk test. 
One-way ANOVA with post-hoc Bonferroni, or Kruskal-Wallis 
with post-hoc Dunns test, as appropriate, was used to analyse 
differences in mRNA and protein expression according to 
Braak stages and SNP genotype. Parametric Pearson’s or 
non-parametric Spearman’s correlation was used to assess any 
relationship between proteins. A multiple regression model 
(STATA v12; StataCorp LLC; Texas, USA) was used to analyse 
mRNA expression in relation to Braak stage pathology, patient 
age of death and tissue post-mortem delay. Where necessary, 
data were transformed to normality before regression analysis. 




With exclusion criteria, the study cohort comprised 47 AD cases 
and 39 controls, as detailed in Table 1. The age of AD cases 
ranged from 54-98 y (mean 81, SD 9). Control cases ranged 
from 43-95 y (mean 80, SD 11). There were more females 
(n = 29) than males (n = 18) in the AD group, and fewer 
females (n = 15) than males (n = 24) in the controls. The PMD 
did not differ significantly between AD (37 h, SD 19) and 
controls (34 y, SD 20; two-tailed Mann-Whitney p = 0.34). 
There was no influence of PMD on RBFOX3 (NeuN) mRNA 
(normalised to GAPDH; n =70, Spearman r = -0.09, p = 0.47) 
or protein level (normalised to GAPDH; n = 79, Spearman 
r = -0.02, p = 0.87).
Significant increase in kinesin gene expression linked to 
AD pathology
Expression of kinesin relative to RBFOX3 mRNA was measured 
by qPCR and analysed in relation to Braak tangle stage. KIF5A 
mRNA was significantly elevated at Braak stages III-IV (p < 0.01) 
and V-VI (p < 0.001), compared to stages I-II, (Figure 2A). 
KLC1 mRNA was significantly elevated in late Braak stage 
disease (V-VI, p < 0.001) compared to stages I-II (Figure 2B). In 
a previous study we found an association between PMD and the 
level of KIF5A relative to RBFOX3 (NeuN) mRNA25 but in the 
present cohort we found no effect of either patient age at death 
or PMD on expression of KIF5A or KLC1 relative to RBFOX3 
(Table 3).
Single nucleotide polymorphisms within the KIF5A gene 
locus influence KIF5A mRNA expression
We previously showed that KIF5A protein level was reduced 
in post-mortem brain tissue from MS patients homozygous for 
SNPs within the KIF5A gene locus which have been linked 
to MS susceptibility24. We explored this in AD brain tissue 
using pre-designed TaqMan® SNP assays for rs12368653 and 
rs4646536, the latter in linkage disequilibrium (r2 = 1) with 
rs703842, making it suitable as a proxy34,35. The accuracy of 
the SNP was verified using 18 MS positive control genotypes 
from our previous studies24.
KIF5A mRNA expression was significantly lower in AD patients 
homozygous for the rs12368653 SNP (AA) than in AD patients 
with no copies (GG) (p<0.05; Figure 3A). Similarly, AD patients 
homozygous for the rs4646536 SNP (AA) (proxy for rs703842), 
had significantly lower KIF5A mRNA than did heterozygous 
patients (AG) (p<0.05; Figure 3B). There was no significant 
difference in KLC1 mRNA expression in AD patients stratified 
according to KIF5A SNPs (rs12368653 and rs4646536; 
Figure 3C and 3D). We subsequently investigated whether 
SNPs in the KLC1 gene that were previously linked to AD 
Figure 2. Upregulation of kinesin mRNA in Alzheimer’s disease. Quantitative real-time PCR on cDNA from mid-frontal cortex of control 
and AD cases showed a significant increase in KIF5A mRNA in Braak stages III-IV (n=11) and V-VI (n=35) compared with Braak stages 0-II 
(n=27) (A). KLC1 mRNA was significantly increased in Braak stages V-VI (n=28) but not stages III-IV (n=12), compared with Braak 
stages 0-II (n=31) (B). Results expressed as median, IQR and min/max quartile. Statistical test used: Kruskal-Wallis with post-hoc Dunns 
(A–B), **p<0.01, ***p<0.001. AD: Alzheimer’s disease, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light 
chain-1, RBFOX3: RNA Binding Fox-1 Homolog 3.
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Table 3. Multiple regression analysis of cohort variables on kinesin mRNA expression.





Braak III-IV 16.14 6.08 2.66 0.01 4.01 28.27
Braak V-VI 31.12 3.90 7.98 0.00 23.33 38.91
Age at death 0.08 0.20 0.40 0.69 -0.33 0.49
Post-mortem 
delay 0.02 0.10 0.15 0.88 -0.19 0.22
KLC1 to  
RBFOX3 mRNA 70
Braak III-IV -0.35 0.17 -2.04 0.05 -0.69 -0.01
Braak V-VI -0.77 0.12 -6.43 0.00 -1.01 -0.53
Age at death -0.00 0.01 -0.69 0.50 -0.02 0.01
Post-mortem 
delay -0.00 0.00 -0.09 0.93 -0.01 0.00
Significant correlations highlighted in red. Abbreviations: KIF: kinesin superfamily protein; KLC1: kinesin light  
chain-1; RBFOX3; RNA Binding Fox-1 Homolog 3.
Figure 3. Significant reduction in KIF5A mRNA expression in patients homozygous for SNPs within KIF5A gene locus. Homozygous 
AD carriers of rs12368653 ‘A’ risk allele, (linked to MS susceptibility), had significantly lower levels of KIF5A mRNA (AA; n=6) than did 
non-carriers (GG; n=10) (A). Homozygous AD carriers of rs703842 ‘A’ risk allele, (identified by proxy SNP rs4646536), also linked to MS 
susceptibility showed significant reduction in KIF5A mRNA (AA; 18) compared to expression in heterozygous carriers (AG; n=17) (B). No 
significant difference in KLC1 mRNA between homozygous (AA; n=6) or heterozygous (AG; n=22) AD carriers of rs12368653 ‘A’ risk allele, 
(linked to MS susceptibility), compared to non-carriers (GG; n=8) (C). Homozygous (AA; n=17) or heterozygous (AG; n=14) AD carriers of 
rs703842 ‘A’ risk allele, (identified by proxy SNP rs4646536), also linked to MS susceptibility, showed no significant difference in KLC1 mRNA 
compared to non-carriers (GG; n=5) (D). Results expressed as median, IQR and min/max quartile. Statistical test used for A and C: one-way 
ANOVA, post-hoc Bonferroni Multiple Comparison. Statistical test used for B and D: Kruskal-Wallis test, post-hoc Dunn’s Multiple Comparison; 
* p<0.05. AA: homozygous adenine, AD: Alzheimer’s disease, AG: adenine/guanine, GG: homozygous guanine, IQR: inter-quartile range, 
KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, MS: multiple sclerosis, RBFOX3: RNA Binding Fox-1 Homolog 3, SNP: single 
nucleotide polymorphism.
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susceptibility21,22 influence kinesin mRNA expression. There was 
no significant difference in KLC1 mRNA between AD patients 
heterozygous for the rs8702 SNP (GC) and those with no copies 
(GG; Figure 4A). Similarly, there was no significant differ-
ence in KLC1 mRNA between AD patients heterozygous for the 
rs8007903 SNP (AG) and those with no copies (AA; Figure 4B). 
Due to low cases numbers (n=2), homozygous expression 
could not be analysed. There was no significant effect of KLC1 
SNPs on KIF5A mRNA expression (Figure 4C and 4D).
Kinesin protein level does not vary significantly with AD 
pathology
Kinesin protein expression was measured by dot blot. In keep-
ing with previous studies25, KIF5A expression did not differ 
significantly between Braak stages 0-II, III-IV and V-VI 
(Figure 5A). In addition, there was no significant variation in KLC1 
protein level with Braak stage (Figure 5B). As expected, the levels 
of KIF5A and KLC1 protein were positively correlated (p < 0.001, 
Figure 5C). There was no influence of SNPs within the KIF5A gene 
locus (rs12368653 and rs4646536) on KIF5A (Figure 6A and 6B) 
or KLC1 protein level (Figure 6C and 6D).
Kinesin levels inversely correlate with amyloid precursor 
protein in AD
As in previous studies25,36, APP level did not differ signifi-
cantly between AD and control cases (Figure 7A). APP levels 
correlated inversely with both KIF5A and KLC1 protein in AD 
(p < 0.05; Figure 7B and 7C). Neither KIF5A or KLC1 corre-
lated with the level of soluble or insoluble Aβ or with the ratio of 
soluble: insoluble Aβ (Table 3), although a trend was seen 
for lower levels of soluble Aβ to be associated with higher 
levels of KIF5A (p=0.10; Table 3), as in our previous study25. As 
expected, soluble and insoluble Aβ levels were significantly 
higher in AD than controls (Figure 8A and 8B).
KIF5A protein level correlates inversely with soluble paired 
helical filament tau
The level of hyperphosphorylated tau in the soluble protein 
fraction was significantly increased in AD compared with con-
trol cases (Figure 9A). The level correlated inversely with 
KIF5A protein level (p<0.05) but not with KLC1 protein in AD 
(Figure 9B and 9C). Western blot analysis showed additional 
bands above the predicted molecular weight of tau (45-65kDa), 
Figure 4. No effect of SNPs within the KLC1 gene on kinesin mRNA expression. No difference in KLC1 mRNA between heterozygous 
carriers of rs8702 ‘C’ risk allele linked to AD susceptibility (GC; n=14) and non-carriers (GG; n=21) (A). No difference in KLC1 mRNA between 
heterozygous carriers of rs8007903 ‘G’ risk allele linked to AD susceptibility (AG; n=7) and non-carriers (AA; n=26) (B). No difference in 
KIF5A mRNA between heterozygous carriers of rs8702 ‘C’ risk allele linked to AD susceptibility (GC; n=17) and non-carriers (GG; n=24) 
(C). No difference in KIF5A mRNA between heterozygous carriers of rs8007903 ‘G’ risk allele linked to AD susceptibility (AG; n=9) and 
non-carriers (AA; n=29) (D). Results expressed as median, IQR and min/max quartile. Statistical test used: two-tailed Mann-Whitney. AA: 
homozygous adenine, AD: Alzheimer’s disease, AG: adenine/guanine, GC: guanine/cytosine, GG: homozygous guanine, IQR: inter-quartile 
range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, MS: multiple sclerosis, RBFOX3: RNA Binding Fox-1 Homolog 3, SNP: 
single nucleotide polymorphism.
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Figure 5. No change in conventional kinesin expression in Alzheimer’s disease. No significant difference in KIF5A between Braak 
stages 0-II (n=29), III-IV (n=12) and V-VI (n=34), on dot blot analysis of protein extracted from homogenised control and AD mid-frontal 
cortex (A). No difference in KLC1 protein between Braak stages 0-II (n=28), III-IV (n=11) and V-VI (n=35) (B). Protein levels of KIF5A 
correlated positively with that of KLC1 (n=86; C). Results expressed as median, IQR and min/max quartile. Statistical test used: Kruskal-
Wallis test, post-hoc Dunn’s Multiple Comparison (A–B). Spearman correlation represented as line of best fit +/- 95% CI (C); ***p<0.001. AD: 
Alzheimer’s disease, CI: confidence intervals, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, NeuN: 
neuronal nuclear protein.
most likely attributed to phosphorylated epitopes37. In addition to 
immunoblotting, hyperphosphorylated tau levels were measured 
by quantitative immunohistochemistry and showed a significant 
positive correlation with hyperphosphorylated tau protein 
levels measured by dot blot (p<0.001; Figure 9D). There was 
no correlation between KIF5A or KLC1 protein level and 
insoluble tau load (Table 4).
Discussion
Previous studies in mouse models implicated defective 
functioning of KLC1 in disruption of axonal transport in AD19,38. 
In the current study of human tissue from AD and control 
cases, we have found KLC1 and KIF5A gene expression to be 
elevated in AD and associated with Braak tangle stage. We have 
also demonstrated significant inverse correlations between 
kinesin levels and AD-associated proteins, emphasising the 
importance of kinesins in AD pathology. We did not find any 
association between KLC1 gene expression and KLC1 SNPs 
reportedly linked to AD.
Four KLC genes are expressed in mammals but those involved 
in axonal transport are KLC1 and KLC2. KLC1 is neuronally 
enriched whereas KLC2 is ubiquitously expressed39. A coiled-
coil region at the amino terminus of the KLCs binds to the 
stalk domain (close to the carboxyl terminus) of conventional 
kinesins (KIF5A, KIF5B and KIF5C) and acts as an adaptor 
complex for indirect binding and transport of cellular cargoes, 
such as APP27.
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Figure 6. Kinesin protein expression in AD patients homozygous for SNPs within the KIF5A gene locus. No difference in KIF5A 
protein between homozygous AD carriers of rs12368653 ‘A’ risk allele, linked to MS susceptibility, (AA; n=9) and heterozygotes (AG; n=21) or 
non-carriers (GG; n=6) (A). No difference in KIF5A protein between homozygous AD carriers of rs703842 ‘A’ risk allele, (identified by proxy 
SNP rs4646536) linked to MS susceptibility, (AA; 15) and heterozygotes (AG; n=17) or non-carriers (GG; n=4) (B). No difference in KLC1 
protein between homozygous AD carriers of rs12368653 ‘A’ risk allele, linked to MS susceptibility, (AA; n=6) and heterozygotes (AG; n=21) 
or non-carriers (GG; n=10) (C). No difference in KLC1 protein between homozygous AD carriers of rs703842 ‘A’ risk allele, (identified by 
proxy SNP rs4646536) linked to MS susceptibility, (AA; 17) and heterozygotes (AG; n=17) or non-carriers (GG; n=5) (D). Results expressed 
as median, IQR and min/max quartile. Statistical test used: one-way ANOVA, post-hoc Bonferroni Multiple Comparison. AA: homozygous 
adenine, AD: Alzheimer’s disease, AG: adenine/guanine, GG: homozygous guanine, IQR: inter-quartile range, KIF: kinesin superfamily 
protein, KLC1: kinesin light chain-1, MS: multiple sclerosis, NeuN: neuronal nuclear protein.
Expression of both KLC1 and KIF5A mRNA was positively 
associated with Braak tangle stage, a widely used marker of AD 
progression, defined by the distribution of hyperphosphorylated 
tau pathology distribution within the brain40. KIF5A mRNA 
was upregulated at relatively early stages of disease (Braak 
stages III-IV), in keeping with previously reported evidence of 
early-stage axonal abnormalities in AD and other neurodegen-
erative diseases13,19,38. Upregulation of both KIF5A and KLC1 
mRNA may be a compensatory response to other pathological 
processes that interfere with axonal transport of protein cargoes 
to the synapse. Elevated kinesin gene expression in human 
tissue has been demonstrated in several neurodegenerative 
diseases15,26,41. 
Genome-wide association studies (GWAS) have shown linkage 
of multiple genes to AD susceptibility, including some genes 
encoding proteins with roles in axonal transport and cytoskeletal 
function (NME8, CELF1, and CASS4)3. However, GWAS are 
unable to detect rare variants linked to susceptibility. Such vari-
ants include SNPs within the KLC1 gene, which have been linked 
to early AD pathogenesis. In particular, rs8702 was reported to 
predict conversion from mild cognitive impairment to AD and 
was associated with levels of hyperphosphorylated tau in patient 
cerebrospinal fluid16. It is hypothesised that this SNP could 
influence the splicing of c-terminal epitopes in KLC1 gene 
transcripts16, which could affect cargo binding affinity, axonal 
transport and synaptic function, causing structural instability 
and eventual neuronal degeneration. The effective ‘strain’ on the 
neuron caused by transport defects is likely to be exacerbated by 
a reduction in mitochondrial ATP supply associated with aging42. 
We found no effect on KLC1 expression of heterozygosity of the 
rs8702 ‘C’ risk allele or rs8007903 ‘G’ allele but did not have 
sufficient cases to analyse the influence of homozygosity of the 
SNPs. Larger genetic studies found no effect of rs8702 on AD 
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Figure 7. Kinesin levels correlate inversely with APP expression in AD. No significant difference in APP between control (n=36) and AD 
cases (n=40) on dot blot analysis of protein extracted from homogenised control and AD mid-frontal cortex (A). Significant inverse correlation 
between KIF5A (normalised to GAPDH) and APP (normalised to NeuN) protein levels in AD (n=38; B). KLC1 level (normalised to GAPDH) 
correlated inversely with APP level (normalised to NeuN) in AD cases (n=37; C). Results expressed as median, IQR and min/max quartile. 
Statistical test used two-tailed t-test (A). Pearson correlations represented as line of best fit +/- 95% CI (B–C); *p<0.05. AD: Alzheimer’s 
disease, APP: amyloid precursor protein, CI: confidence intervals, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin 
light chain-1, NeuN: neuronal nuclear protein.
susceptibility but a significant interaction with APOE ε4 carrier 
status in patients16. The continuing uncertainty as to the 
influence of KLC1 polymorphisms on the risk of AD highlights 
the difficulties of linkage studies for rare variants, which are 
often hampered by small sample size, locus heterogeneity and 
false-positive results3.
We previously found a significant reduction in KIF5A expres-
sion in MS tissue in homozygous carriers of the rs703842 ‘A’ 
allele and rs12368653 ‘A’ allele23,24, which are linked to MS 
susceptibility34,43. GWAS have identified susceptibility variants 
common to MS and sporadic AD, including major histocom-
patibility complex gene HLA-DRB13. In the present study, we 
found a significant reduction in KIF5A mRNA expression in 
AD patients homozygous for the rs4646536 ‘A’ allele (proxy for 
rs70384235) and rs12368653 ‘A’ allele, compared to heterozy-
gotes and non-carriers. Variability within the KIF5A gene locus 
may be a common denominator across a spectrum of neurode-
generative conditions. KIF5A mutations are linked to several 
axonopathies, including hereditary spastic paraplegia and 
Charcot-Marie Tooth Disease44,45. More recently, a mutation in 
the cargo binding domain of KIF5A was shown to be associated 
with amyotrophic lateral sclerosis46. These findings highlight the 
importance of KIF5A for axonal transport and maintenance of 
neuronal function and integrity.
Unlike our findings in MS, although the KIF5A genotype 
influenced mRNA expression in AD it did not have a detectable 
effect on expression of the protein. We previously found increased 
KIF5A protein in AD, although no significant association with 
Braak stage25. Similarly, in the present study we found no 
significant association between KIF5A or KLC1 and Braak 
stage. It is possible that reduced protein clearance, a common 
finding in age-related neurodegenerative diseases47, could partly 
compensate for reduced KIF5A synthesis in the later stages 
of AD. Aβ itself may influence kinesin metabolism. Previous 
studies found reduced KLC1 protein in AD frontal cortex48 
and reduced KLC1 expression in the presence of soluble Aβ 
trimers49. Assay sensitivity may also be relevant and some 
changes in KLC1 metabolism missed due to the complex car-
boxyterminal splicing, which results in multiple variants50 with 
varied affinities for the antibody used in the present study. 
Co-immunoprecipitation studies have demonstrated at least 6 
variants of conventional kinesin (KIF- 5A/5B/5C with KLC1 or 
KLC2); however, with alternative splicing of KLC1 the number 
is likely to be much higher28. The multiplicity of splice variants 
is attributed to the large variety of membrane cargoes that require 
transportation to distinct neuronal compartments1.
Irrespective of overall kinesin protein levels, evidence points 
to disruption of convention kinesin transport in AD, through 
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Figure 8. Expression of Aβ in mid-frontal cortex. Soluble Aβ significantly increased in AD cases (n=40) compared with control (n=18) from 
ELISA analysis (A). Insoluble Aβ significantly higher in AD cases (n=41) compared to control (n=23; B). Results expressed as median, IQR 
and min/max quartile. Statistical test used: two-tailed Mann-Whitney; **p<0.01. Aβ: amyloid beta, AD: Alzheimer’s disease, IQR: inter-quartile 
range.
Figure 9. KIF5A levels correlate inversely with hyperphosphorylated tau expression in Alzheimer’s disease. Significant increase 
in PHF-tau in AD cases (n=44) compared with control (n=35; A). Significant inverse correlation between KIF5A (normalised to GAPDH) 
and PHF-Tau (normalised to NeuN) in AD (n=44; B). No significant correlation between KLC1 levels (normalised to GAPDH) and PHF-
Tau protein (normalised to NeuN) in AD (n=44; C). The level of soluble PHF-Tau (as measured by dot blot) showed a significant positive 
correlation with insoluble hyperphosphorylated tau load (as determined by IHC) in AD cases (n=44; D). Results expressed as median, IQR 
and min/max quartile. Statistical test used two-tailed Mann-Whitney (A). Spearman correlations represented as line of best fit +/- 95% CI 
(B–D); *p<0.05, ***p<0.001. AD: Alzheimer’s disease, CI: confidence intervals, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, IHC: 
immunohistochemistry, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, NeuN: neuronal nuclear protein, 
PHF: paired helical filament.
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phosphorylation-mediated dissociation of KIF from both its 
cargo and from the microtubule51. Studies of transgenic mouse 
models have suggested that Aβ can be transported within neu-
rites and have shown a correlation between axonal swellings 
positive for intracellular Aβ and the location of extracellular 
insoluble Aβ deposits20. In addition, studies in the squid giant 
axon have shown that Aβ oligomers can inhibit axonal transport 
through activation of casein kinase 2, which phosphorylates 
KLC1, reducing its cargo binding affinity52,53. We found no sig-
nificant correlation between KIF5A or KLC1 and insoluble 
Aβ levels, despite a trend towards lower soluble Aβ with higher 
KIF5A, as in our previous study25. There was a significant 
negative correlation between KIF5A and soluble hyperphos-
phorylated tau levels, but not with the insoluble tau load as 
determined immunohistochemically. Pathogenic forms of tau 
enhance glycogen synthase kinase 3β (GSK3β) activity by 
increasing exposure of the phosphatase-activating domain in 
the amino terminus of tau, which increases protein-phosphatase 
1-dependent activation of GSK3β54. Elevated GSK3β causes 
KLC1 phosphorylation and results in protein cargo dissociation38.
As kinesin phosphorylation is a potent modulator of axonal 
transport in neurodegenerative diseases, this pathway presents 
a potential modifiable target for treatment1,55. However, evidence 
suggests cargo transport is bi-directional in axons with both 
anterograde motor kinesin and retrograde motor dynein bound 
simultaneously in a ‘tug-of-war’ model, such that the loss or 
post-translation modification of one motor protein will affect 
motility in both directions56,57. Indeed, studies have reported 
reduced dynein intermediate chain in AD cortex48. In addition, 
protein kinases regulate a wide range of cellular activities, and 
for any attempted therapeutic interventions it will be important to 
establish the specificity of kinase inhibitors and phosphatases on 
kinesin expression.
Overall, the findings from this study do not indicate that 
upregulation of KIF5A is a result of functional redundancy 
between KIF5A and KLC1 in protein transport, or that the 
expression of KLC1 in cerebral cortex is influenced by KLC1 
polymorphisms, which have been linked to AD susceptibility. 
However, the findings highlight the importance of KIF5A in 












Control 33 -0.27 0.13
AD 38 -0.41 0.01
PHF-tau 
Control 35 -0.17 0.35
AD 44 -0.36 0.02
Tau load AD 42 0.10 0.52
Insoluble Aβ 
Control 22 0.25 0.25
AD 37 -0.13 0.46
Soluble Aβ 
Control 19 0.14 0.58
AD 37 -0.28 0.10
Soluble: 
Insoluble Aβ 
Control 14 -0.06 0.84
AD 32 0.02 0.90
KLC1 
APP 
Control 34 -0.28 0.11
AD 37 -0.34 0.04
PHF-Tau 
Control 33 -0.28 0.11
AD 37 -0.24 0.14
Tau load AD 43 -0.05 0.73
Insoluble Aβ 
Control 22 0.29 0.20
AD 39 0.03 0.88
Soluble Aβ 
Control 19 0.15 0.35
AD 33 0.02 0.93
Soluble: 
Insoluble Aβ 
Control 14 -0.15 0.62
AD 33 0.12 0.52
Significant correlations highlighted in red. Abbreviations: Aβ: amyloid beta;  
APP: amyloid precursor protein; KIF: kinesin superfamily protein; KLC1: kinesin light 
chain-1; PHF: paired helical filament.
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maintaining axonal transport and raise the possibility that 
patients with higher ‘reserve’ levels of KIF5A are less suscep-
tible to axonal transport disruption and pathology. The findings 
also suggest genetic polymorphisms within the KIF5A gene 
locus could represent a common neurodegenerative pathway 
across a spectrum of neurological conditions.
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